JP2019500346A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500346A5
JP2019500346A5 JP2018529237A JP2018529237A JP2019500346A5 JP 2019500346 A5 JP2019500346 A5 JP 2019500346A5 JP 2018529237 A JP2018529237 A JP 2018529237A JP 2018529237 A JP2018529237 A JP 2018529237A JP 2019500346 A5 JP2019500346 A5 JP 2019500346A5
Authority
JP
Japan
Prior art keywords
mrna
peroxisome proliferator
activated receptor
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018529237A
Other languages
English (en)
Japanese (ja)
Other versions
JP7049247B2 (ja
JP2019500346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/066576 external-priority patent/WO2017106292A1/en
Publication of JP2019500346A publication Critical patent/JP2019500346A/ja
Publication of JP2019500346A5 publication Critical patent/JP2019500346A5/ja
Priority to JP2022013876A priority Critical patent/JP2022062143A/ja
Application granted granted Critical
Publication of JP7049247B2 publication Critical patent/JP7049247B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018529237A 2015-12-14 2016-12-14 腎臓病の処置のための組成物と方法 Expired - Fee Related JP7049247B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022013876A JP2022062143A (ja) 2015-12-14 2022-02-01 腎臓病の処置のための組成物と方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267242P 2015-12-14 2015-12-14
US62/267,242 2015-12-14
PCT/US2016/066576 WO2017106292A1 (en) 2015-12-14 2016-12-14 Compositions and methods for treatment of kidney diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022013876A Division JP2022062143A (ja) 2015-12-14 2022-02-01 腎臓病の処置のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2019500346A JP2019500346A (ja) 2019-01-10
JP2019500346A5 true JP2019500346A5 (cg-RX-API-DMAC7.html) 2020-01-30
JP7049247B2 JP7049247B2 (ja) 2022-04-06

Family

ID=59057520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529237A Expired - Fee Related JP7049247B2 (ja) 2015-12-14 2016-12-14 腎臓病の処置のための組成物と方法
JP2022013876A Pending JP2022062143A (ja) 2015-12-14 2022-02-01 腎臓病の処置のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022013876A Pending JP2022062143A (ja) 2015-12-14 2022-02-01 腎臓病の処置のための組成物と方法

Country Status (4)

Country Link
EP (1) EP3390666A4 (cg-RX-API-DMAC7.html)
JP (2) JP7049247B2 (cg-RX-API-DMAC7.html)
CA (1) CA3005249A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017106292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
KR102422625B1 (ko) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN118325899A (zh) 2017-01-23 2024-07-12 瑞泽恩制药公司 Hsd17b13变体及其应用
RU2019135845A (ru) 2017-04-11 2021-05-11 Ридженерон Фармасьютикалз, Инк. Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b)
CN111278991B (zh) 2017-08-25 2022-04-01 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
EP4234719B1 (en) 2017-10-11 2025-11-26 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
BR112020018758A2 (pt) 2018-03-21 2021-01-26 Regeneron Pharmaceuticals, Inc. agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2019236995A1 (en) * 2018-06-08 2019-12-12 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
US12422440B2 (en) 2018-10-05 2025-09-23 Seattle Children's Hospital Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease
WO2020154462A1 (en) * 2019-01-23 2020-07-30 Rogcon U.R., Inc. Antisense oligonucleotides targeting scn2a retained introns
WO2021034985A1 (en) * 2019-08-19 2021-02-25 Stoke Therapeutics, Inc. Compositions and methods for modulating splicing and protein expression
JP2023519969A (ja) 2020-03-31 2023-05-15 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート リソソーム蓄積症に関するプロテオミクススクリーニング
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224514A1 (en) * 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of PPAR-delta expression
CA2588646A1 (en) * 2004-11-19 2006-05-26 Acadia Pharmaceuticals Inc. Methods to identify ligands of hormone nuclear receptors
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US20140128449A1 (en) * 2011-04-07 2014-05-08 The Board Of Regents Of The University Of Texas System Oligonucleotide modulation of splicing
US9909128B2 (en) * 2012-11-15 2018-03-06 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
PL3041958T3 (pl) * 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
CN107109411B (zh) * 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加

Similar Documents

Publication Publication Date Title
JP2019500346A5 (cg-RX-API-DMAC7.html)
JP2019501892A5 (cg-RX-API-DMAC7.html)
JP2022062140A5 (cg-RX-API-DMAC7.html)
JP2019500347A5 (cg-RX-API-DMAC7.html)
JP2019500349A5 (cg-RX-API-DMAC7.html)
JP2018538288A5 (cg-RX-API-DMAC7.html)
JP2018538287A5 (cg-RX-API-DMAC7.html)
US20230203483A1 (en) Compositions and Methods Using SNRNA Components
JP2019500350A5 (cg-RX-API-DMAC7.html)
JP2017536338A5 (cg-RX-API-DMAC7.html)
JP2019500345A5 (cg-RX-API-DMAC7.html)
EP2027267B1 (en) Means and method for inducing exon-skipping
CN107406852B (zh) 用于莱伯氏先天性黑蒙的寡核苷酸疗法
AU2017379073B2 (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
AU2010335039B2 (en) Molecule for treating an inflammatory disorder
KR20080031164A (ko) ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
EP3353301A1 (en) Antisense oligonucleotides and uses thereof
CN113195721A (zh) 治疗α-1抗胰蛋白酶缺乏症的组合物和方法
US20200407721A1 (en) Compounds of chemically modified oligonucleotides and methods of use thereof
JP7760130B2 (ja) Ａｐｏｃ３を標的としたアンチセンス核酸
Benchaouir et al. Splicing modulation mediated by small nuclear RNAs as therapeutic approaches for muscular dystrophies
US20250327093A1 (en) Viral vector and cancer cell proliferation inhibitor comprising the same
JPWO2019213525A5 (cg-RX-API-DMAC7.html)
EP3690046A2 (en) Composition for treatment of hemophilia, comprising crispr/cas system having coagulation factor viii gene inversion correction potential
CA2999192C (en) Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof